期刊文献+

抗高血压药马西替坦的合成工艺优化 被引量:2

Process Optimization for Synthesis of Antihypertensive Agent Macitentan
原文传递
导出
摘要 以4-溴苯乙酸甲酯为起始原料,经碳负离子亲核取代、关环、氯代、氮负离子亲核取代、氧负离子亲核取代等6步反应制得抗高血压药马西替坦,并对合成工艺进行了优化。优化后的工艺使中间体的纯度得到了提高,操作更加简便,更有利于工业化生产。中间体和产物的结构均经~1H-NMR和ESI-MS确证。 Using methyl 4-bromophenylacetate as the starting material,Macitentan was synthesized by a 6-step reaction of nucleophilic substitution of carbon anion,ring-closing reaction,chlorination,nucleophilic substitution of nitrogen anion, nucleophilic substitution of oxygen anion, and the synthetic process was also optimized. The structures of the intermediates and products were confirmed by ~1 H-NMR and ESI-MS. The optimized process improves the purity of the intermediate,the operation is more simple and more conducive to industrial production.
作者 尹贻虎 薛玉涛 窦春水 姚庆强 Yin Yihu, Xue Yutao, Dou Chunshui, Yao Qingqiang(School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences ; Institute of Materia Medical, Shandong Academy of Medical Sciences; Key Laboratory for Biotech-Drugs Ministry of Health; Key Laboratory for Rare & Uncommon Diseases of Shandong Province, Jinan 25006)
出处 《化学通报》 CAS CSCD 北大核心 2018年第4期380-383,共4页 Chemistry
关键词 马西替坦 合成 高血压 Macitentan Synthesis Hypertension
  • 相关文献

参考文献1

二级参考文献5

  • 1FDA. FDA approves Opsumit to treat pulmonary arterial hy- pertension [ EB/OL ]. [ 2013 - 10 - 18 ]. http://www, fda. gov/NewsEv ucm371362, htm.
  • 2BOLLI M H, BOSS C, BINKERT C, et al. The discovery of N-[ 5-( 4-bromophenyl )-6-[ 2-[ ( 5-bromo-2-pyrimidinyl ) oxy ]ethoxy ] -4-pyrimidinyl ] -N'-propylsulfamide ( Maciten- tan), an orally active, potent dual endothelin receptor antago- nist [ J ]. J Med Chem,2012,55 ( 17 ) :7849 - 7861.
  • 3BOSS C, FISCHILI W, WELLER T, et al. Novel sulfamides: WO,2006051502 [ P]. 2006 - 05 - 18.
  • 4BREDERER S, HOPFGARTNER G R, SEIBERLING M, et al. Absorption, distribution, metabolism and excretion of ma- citentan, a dual endothelin receptor antagonist, in humans [ J ]. Xenobiotica, 2012,42 ( 9 ) : 901 - 910.
  • 5Actelion. Actelion receives US FDA approval of Opsumit( ma- citentan) for the treatment of pulmonary medal hypertension [ EB/OL]. [ 2013 - 10 - 18 ]. http://www, actelion, com/ en/our-company/news-and-events/index, page? newsId = 1736781.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部